Overview In January 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published new recommendations for hereditary breast cancer genetic testing (1)..
Aiming to evaluate the role of chromosomal aneuploidy in pregnancy loss, a 2023 study 35 years in the making evaluated the genomic landscape of first-trimester spontaneous pregnancy loss [1]. The aim..
A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized therapy for cancer patients by integrating genetic wi..
Aneuploidies, such as translocations, whole or segmental chromosomal duplications, and deletions, are examples of chromosomal abnormalities that are estimated to affect approximately 1 in 150 live bi..
In June 2023, Medicover Genetics attended the 56th conference of the European Society of Human Genetics (ESHG) which took place in Glasgow, Scotland. The ESHG conference, which is organized annually,..
A recent article published by our team in the International Journal of Molecular Sciences [1], aimed to evaluate the prevalence, prognostic and predictive values of gene mutations in patients with pr..
Colorectal cancer (CRC) in adolescents and young adults (AYA) is rare. Genetic causes include autosomal recessive and dominant monogenic disorders due to pathogenic variants (PVs) in genes involved i..
Scientists have discovered two distinct types of obesity with physiological and molecular differences that may have lifelong implications for health, disease, and drug response. The study, published ..
Medicover Genetics attended the 55th edition of the largest genetics conference in Europe, European Human Genetics Conference, held in Vienna, from 11 to 14 June 2022. The main goal of the confe..
69 distinct genetic variations associated with the ability to keep in time with a musical beat (also called beat synchronization ability) have been discovered by an international team of researchers...
Medicover Genetics’ technology transfer platform offers comprehensive testing in a single sequencing run, making it a unique and efficient solution for laboratories of any size. With our Technology Transfer platform, laboratories can perform multi-disciplinary genetic tests such as NIPT, cardiac, hereditary cancer, carrier screening, and metabolic testing all in a single sequencing run. This improves turnaround time and reduces operational costs while ensuring high-quality results with no compromise on accuracy. Our comprehensive testing approach is ideal for laboratories looking to provide a wide range of genetic tests to their healthcare associates and patients.
Our Technology Transfer platform workflow is designed to minimize the risk of errors, reduce hands-on processing and increase the accuracy of test results, providing confidence to patients and physicians in making informed decisions with our user-friendly protocols. The implementation of these protocols ensures that laboratory personnel are trained to follow standardized procedures, reducing the likelihood of human error, and increasing the quality of results.
Medicover Genetics’ versatile Technology Transfer platform can be integrated in a single workflow, offering a multidisciplinary portfolio of genetic tests. VERACITY, VERACITY High Content (HC) and TarCET IVD kits are CE-marked and include user friendly color identification formatting. VERACITY and VERACITY HC kits contain 96 reactions and TarCET IVD kits contain 16 reactions.
We work closely with laboratories to meet their unique needs and goals. We understand that every laboratory is different, and we tailor our approach to accommodate the specific requirements of each partner. In collaboration with our partners, we design a seamless integrated process, from initial setup to ongoing support and maintenance. Our experienced team provides technical, commercial, and marketing assistance to ensure a successful partnership and optimal performance. We aim to build long-lasting partnerships that are mutually beneficial.
